80 completed, 20 terminated, 15 recruiting, 15 unknown. 74 Phase 2, 59 Phase 1, 8 Not applicable, 8 Phase 3, 2 Phase 4.
Follow Peripheral T-Cell Lymphoma: new trials by email Literature Review of Peripheral T-Cell Lymphoma trials Research Report on Peripheral T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of CAPCT in Patients With PTCL Chidamide, Azacitidine (AZA), Prednisone - Peripheral T-Cell Lymphoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 58 | 2026-08-01 | 2026-08-05 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study Observational - Peripheral T-Cell Lymphoma | Recruiting | Fudan University | 3000 | 2025-11-15 | 2026-03-24 | |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma XNW5004 combined with CHOP (incremental), XNW5004 combined with CHOEP (incremental), XNW5004 combined with CHOP (extended) - Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Evopoint Biosciences Inc. | 176 | 2025-08-15 | 2026-07-29 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies CHT101 - Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL) | Phase 1 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 24 | 2025-03-31 | 2025-04-06 |
| Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma chidamide and golidocitinib - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 45 | 2024-12-30 | 2025-01-03 |
| Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients BCL regimen, Cohort 1 (ASCT-eligible), Cohort 2 (ASCT--ineligible) - Peripheral T-cell Lymphoma | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2024-11-01 | 2025-07-18 |
| Golidocitinib Plus CHOP in Newly Diagnosed PTCL Golidocitinib plus CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 68 | 2024-09-01 | 2024-12-18 |
| Linperlisib Combined With Chidamide in Patients With PTCL Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Yanyan Liu | 134 | 2024-05-25 | 2025-12-05 |
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Golidocitinib, Chidamide, Gemcitabine - Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 218 | 2024-05-13 | 2026-06-08 |
| Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy Systemic therapy - Peripheral T-cell Lymphoma | Completed | Bristol-Myers Squibb | 307 | 2024-04-05 | 2025-06-04 | |
| Circulating Tumor DNA in Peripheral T-cell Lymphomas Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) - Peripheral T-cell Lymphoma, NK/T-Cell Lymphoma | Active not recruiting | University of Aarhus | 50 | 2024-03-01 | 2026-05-01 | |
| A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma SHR2554/CHOP, SHR2554/CHOEP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-12-22 | 2024-05-14 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma Linperlisib in combination with CHOP - Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 44 | 2023-08-15 | 2026-09-16 |
Showing 20 of 141. Sign in to see all of them.
Lymphoma, T-Cell, Peripheral (141) · Lymphoma, T-Cell, Cutaneous (52) · Lymphoma, Large B-Cell, Diffuse (50) · Lymphoma, Non-Hodgkin (49) · Lymphoma, Large-Cell, Anaplastic (48) · Lymphoma, Extranodal NK-T-Cell (46) · Immunoblastic Lymphadenopathy (45) · Leukemia, Lymphocytic, Chronic, B-Cell (45) · Mycosis Fungoides (44) · Lymphoma, Follicular (43) · Sezary Syndrome (43) · Lymphoma, Mantle-Cell (42) · Lymphoma, B-Cell, Marginal Zone (41) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (41)
Hemic and Lymphatic Diseases (141) · Immune System Diseases (141) · Immunoproliferative Disorders (141) · Lymphatic Diseases (140) · Neoplasms by Histologic Type (140) · Lymphoproliferative Disorders (139) · Neoplasms (138) · Lymphoma, T-Cell (130) · Lymphoma (127) · Lymphoma, Non-Hodgkin (92) · Hematologic Diseases (60) · Leukemia, Lymphoid (56) · Leukemia (54) · Disease Attributes (53) · Pathologic Processes (53)
Cyclophosphamide (24) · Prednisone (16) · Etoposide (14) · Peripheral Blood Stem Cell Transplantation (14) · Whole-Body Irradiation (14) · Doxorubicin (13) · Vincristine (13) · fludarabine phosphate (13) · Mycophenolic Acid (12) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (11) · Cyclosporine (10) · Lenalidomide (9) · Gemcitabine (8) · romidepsin (7) · Dexamethasone (6)
Fred Hutchinson Cancer Center (14) · National Cancer Institute (NCI) (10) · Acrotech Biopharma Inc. (4) · Case Comprehensive Cancer Center (4) · Kyowa Kirin Co., Ltd. (3) · Peking Union Medical College Hospital (3) · Ruijin Hospital (3) · Solasia Pharma K.K. (3) · University of Nebraska (3) · Celgene (2) · City of Hope Medical Center (2) · Dizal Pharmaceuticals (2) · Eisai Co., Ltd. (2) · Fudan University (2) · Massachusetts General Hospital (2)
United States (84) · China (29) · Italy (18) · France (10) · United Kingdom (9) · Canada (8) · Germany (8) · Japan (8) · Spain (7) · Belgium (5) · Denmark (4) · South Korea (4) · Thailand (4) · Australia (3) · Israel (3)
David Maloney (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · Andrei Shustov, MD (2) · Ann Woolfrey (2) · Francine Foss, MD (2) · Jeremy Abramson, MD (2) · Julie M Vose (2) · Weili Zhao (2) · Aaron R Mangold, M.D. (1) · Adam Lerner, MD (1) · Adam Petrich, MD (1) · Alain Delmer, MD (1) · Ali Moiin, MD (1) · Amanda Cashen, MD (1)
PMID 32499241, PMID 33051668, PMID 18626005, PMID 18698002, PMID 19900571, PMID 21504290, PMID 22259028, PMID 22271479, PMID 23393050, PMID 24456586, PMID 24474568, PMID 25279222, PMID 25404094, PMID 25605368, PMID 25605745, PMID 26213141, PMID 26764356, PMID 26853648, PMID 26921086, PMID 26943915, PMID 26965915, PMID 27071522, PMID 27418646, PMID 28270022, PMID 28420721, PMID 28597542, PMID 28771889, PMID 29292843, PMID 29363235, PMID 29475723, PMID 29572391, PMID 30301414, PMID 30562587, PMID 30952672, PMID 31388792, PMID 31917843, PMID 32550864, PMID 33236943, PMID 33492438, PMID 33602316, PMID 34230007, PMID 34670169, PMID 34843406, PMID 35332334, PMID 36399518, PMID 36661315, PMID 37319432, PMID 37327113, PMID 38364196, PMID 39175480
P30CA015704 (12), P01CA018029 (4), 2019 (2), P01CA078902 (2), P30CA016672 (2), P30CA036727 (2), P30CA043703 (2), U01CA097452 (2), 2008 (1), N01CM00039 (1), N01CM62202 (1), P01CA044991 (1), P30CA012197 (1), P30CA016056 (1), P30CA016058 (1)